Fab Fragment Pharmaceutical Composition Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Monovalent Fab fragments used in diagnostic drugs face issues with the generation of multimers or insoluble subvisible particles due to heat or light stress, and there is a decrease in coordination efficiency of metal radioisotopes and fluorescence color degradation during preservation.
Innovation Solution
A pharmaceutical composition is formulated with citric acid, phosphoric acid, or 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid as buffering agents, sucrose or glycerin as stabilizers, and a nonionic surfactant, maintaining a pH of 6.5 to 7.5 to prevent particle formation and maintain coordination efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Fab fragments are preserved under conventional conditions, then they maintain their diagnostic function, but multimers and insoluble subvisible particles are generated due to heat or light stress
Solution Approach 1:
The patent applies preliminary action by adding stabilizers (sucrose, glycerin) and buffering agents (citric acid, phosphoric acid, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid) to the formulation before storage. These additives are incorporated in advance to prevent particle formation during subsequent heat or light stress, rather than attempting to remove particles after they form.
Solution Approach 2:
The patent utilizes parameter changes by controlling the pH of the formulation within a specific range (6.5 to 7.5) using buffering agents. This pH control prevents the generation of multimers and insoluble particles during storage, thereby maintaining both the diagnostic function and compositional stability of the Fab fragments.
2Duration of action of stationary object
If Fab fragments are preserved for extended periods, then diagnostic availability is improved, but coordination efficiency of metal radioisotopes decreases
Solution Approach 1:
The patent applies preliminary action by incorporating stabilizers and buffering agents into the formulation before storage to prevent degradation of coordination efficiency during extended preservation. The buffering agents maintain optimal pH conditions that protect the metal radioisotope coordination throughout the storage period.
3Duration of action of stationary object
If Fab fragments are preserved under conventional conditions, then storage duration is extended, but fluorescence color degradation occurs
Solution Approach 1:
The patent applies preliminary action by adding stabilizers (sucrose, glycerin) and buffering agents to the formulation before storage. These additives are incorporated in advance to prevent fluorescence color degradation during subsequent storage, rather than attempting to restore color after degradation occurs.
Solution Approach 2:
The patent utilizes parameter changes by controlling the pH of the formulation within a specific range (6.5 to 7.5) using buffering agents. This pH control prevents fluorescence color degradation during storage, thereby maintaining both the storage duration and compositional stability of the Fab fragments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively suppresses the generation of multimers and insoluble particles, maintains coordination efficiency of metal radioisotopes, and prevents fluorescence color degradation, enhancing stability and usability of the diagnostic drug.
Implementation Method 1
A pharmaceutical composition is formulated with citric acid, phosphoric acid, or 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid as buffering agents, sucrose or glycerin as stabilizers, and a nonionic surfactant, maintaining a pH of 6.5 to 7.5 to prevent particle formation and maintain coordination efficiency.
Implementation Method 2
A pharmaceutical composition is formulated with citric acid, phosphoric acid, or 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid as buffering agents, sucrose or glycerin as stabilizers, and a nonionic surfactant, maintaining a pH of 6.5 to 7.5 to prevent particle formation and maintain coordination efficiency.
Implementation Method 3
A pharmaceutical composition is formulated with citric acid, phosphoric acid, or 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid as buffering agents, sucrose or glycerin as stabilizers, and a nonionic surfactant, maintaining a pH of 6.5 to 7.5 to prevent particle formation and maintain coordination efficiency.
Data Source
AI summary
Provided is a stable pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, and the like. In the pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, citric acid, phosphoric acid, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid or trishydroxymethyl aminomethane is added as a buffering agent, sucrose or glycerin is added as a stabilizer, a nonionic surfactant is added, and the pH is adjusted to 6.5 to 7.5. This enables suppression of generation of multimers and insoluble subvisible particles during preservation of the labeling moiety-anti-human antibody Fab fragment conjugate.